<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Thalia Therapeutics Plc — News on 6ix</title>
    <link>https://6ix.com/company/thalia-therapeutics-plc</link>
    <description>Latest news and press releases for Thalia Therapeutics Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 13 May 2026 10:12:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/thalia-therapeutics-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d589c0beedb30cb6f8d094.webp</url>
      <title>Thalia Therapeutics Plc</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc</link>
    </image>
    <item>
      <title>CEO Interview: Thalia’s RNA Therapeutics Strategy</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/ceo-interview-thalias-rna-therapeutics-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/ceo-interview-thalias-rna-therapeutics-strategy</guid>
      <pubDate>Wed, 13 May 2026 10:12:00 GMT</pubDate>
      <description>Thalia Therapeutics plc announced the release of a video interview with its CEO, Dr. David Solomon, detailing the company&apos;s strategic shift towards high-value RNA therapeutics and its ongoing development of Nuvec®, a proprietary gene delivery system. The interview highlights Thalia&apos;s focus on opportunities within cardiovascular disease and oncology, aiming to address unmet medical needs with its innovative RNA-based treatments and delivery platform.
                Disclaimer*</description>
    </item>
    <item>
      <title>Change of Registered Address</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/change-of-registered-address-38</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/change-of-registered-address-38</guid>
      <pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
      <description>Thalia Therapeutics plc has announced an immediate change to its registered address to 2 Portman Street, London, W1H 6DU. The company, which is developing its proprietary gene delivery system Nuvec® for advanced therapies, made this announcement on April 20, 2026. This administrative update is the sole focus of the RNS release and does not contain any financial performance data or strategic operational changes that would directly impact the stock share price.
                Disclaimer*</description>
    </item>
    <item>
      <title>Result of General Meeting and Change of Name</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/result-of-general-meeting-and-change-of-name-6</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/result-of-general-meeting-and-change-of-name-6</guid>
      <pubDate>Tue, 17 Mar 2026 12:14:00 GMT</pubDate>
      <description>N4 Pharma PLC has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026, with its ticker symbol on the London Stock Exchange changing from N4P to THAT. This rebranding signifies the company&apos;s strategic shift towards becoming a therapeutics-focused biotechnology firm, leveraging its proprietary Nuvec® gene delivery system to advance treatments for cancer and other diseases. Existing share certificates remain valid, and shareholders&apos; holdings are unaffected by the name c</description>
    </item>
    <item>
      <title>Notice of GM and Proposed Change of Name</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/notice-of-gm-and-proposed-change-of-name-1</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/notice-of-gm-and-proposed-change-of-name-1</guid>
      <pubDate>Fri, 27 Feb 2026 07:00:00 GMT</pubDate>
      <description>N4 Pharma plc announced its intention to change its name to Thalia Therapeutics plc, subject to shareholder approval at a general meeting scheduled for March 17, 2026. This proposed name change reflects the company&apos;s strategic shift towards developing innovative RNA-based therapeutics, complementing its existing Nuvec® gene delivery system. The company&apos;s trading identifier will change to THAT, while its LEI, ISIN, and SEDOL will remain the same. Existing share certificates will continue to be va</description>
    </item>
    <item>
      <title>CEO Appointment &amp; Name Change Thalia Therapeutics</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/ceo-appointment-and-name-change-thalia-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/ceo-appointment-and-name-change-thalia-therapeutics</guid>
      <pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
      <description>N4 Pharma plc is transitioning to a therapeutic biotechnology company, proposed to be renamed Thalia Therapeutics, and has appointed Dr. David H. Solomon as CEO to drive the development of RNA-based therapeutics and its Nuvec® delivery platform. The company is initiating a program for a dual-acting siRNA targeting PCSK9 and Lp(a) to reduce cardiovascular risk, a market projected to grow significantly. This strategic shift involves advancing internally generated assets and exploring new opportuni</description>
    </item>
    <item>
      <title>Business and Operational Update</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/business-and-operational-update-3</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/business-and-operational-update-3</guid>
      <pubDate>Wed, 17 Dec 2025 07:00:00 GMT</pubDate>
      <description>N4 Pharma plc provided a business and operational update highlighting progress in its collaboration with the University of Strathclyde on its Nuvec® gene delivery system, with in vitro and in vivo studies planned for early 2026. Latest studies indicate Nuvec® offers significant stability advantages over lipid nanoparticles, crucial for its oral anti-inflammatory product N4 101 and potential partnerships. Key 2025 achievements include successful preclinical demonstration of oral delivery and effi</description>
    </item>
    <item>
      <title>Interim Results</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/interim-results-694</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/interim-results-694</guid>
      <pubDate>Thu, 25 Sep 2025 06:00:00 GMT</pubDate>
      <description>N4 Pharma PLC reported an operating loss of £470,216 for the six months ended June 30, 2025, a reduction from £491,705 in the prior year. The company&apos;s cash position remained strong at £1,727,543, compared to £1,204,946 in the previous year, boosted by a successful placing in April 2025 that raised £1,750,000 in gross proceeds. Basic and diluted loss per share was (0.09p) compared to (0.16p) the previous year. The company issued 87,500,000 warrants at an exercise price of 0.4p per warrant as par</description>
    </item>
    <item>
      <title>Partnership with University of Strathclyde’s CMAC</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/partnership-with-university-of-strathclydes-cmac</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/partnership-with-university-of-strathclydes-cmac</guid>
      <pubDate>Tue, 23 Sep 2025 06:00:00 GMT</pubDate>
      <description>N4 Pharma PLC has announced a collaboration with the University of Strathclyde&apos;s CMAC National Facility to advance its Nuvec® gene delivery platform. The partnership aims to accelerate the platform&apos;s development towards clinical readiness and explore broader therapeutic applications. The collaboration will involve characterizing additional dual-loaded Nuvec® preclinical candidates both in vitro and in vivo. Professor Yvonne Perrie, awarded an MBE in 2024 for services to pharmaceutical innovation</description>
    </item>
    <item>
      <title>N4 Pharma’s Nuvec® Targets Lung Cancer Cells</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/n4-pharmas-nuvecr-targets-lung-cancer-cells</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/n4-pharmas-nuvecr-targets-lung-cancer-cells</guid>
      <pubDate>Mon, 22 Sep 2025 06:00:00 GMT</pubDate>
      <description>N4 Pharma announced positive results from its collaboration with SRI, achieving targeted delivery of therapeutic RNA to non-small cell lung cancer cells using its Nuvec® system. The Nuvec® particles were functionalized with a targeting molecule, demonstrating selective uptake and activity only in the targeted cells compared to untargeted Nuvec®. This validates Nuvec®&apos;s potential as a delivery system for RNA therapeutics across multiple diseases. The global RNA therapeutics market was valued at $</description>
    </item>
    <item>
      <title>Notice of Results, Analyst &amp; Investor Presentation</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/notice-of-results-analyst-and-investor-presentation-3</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/notice-of-results-analyst-and-investor-presentation-3</guid>
      <pubDate>Fri, 19 Sep 2025 06:00:00 GMT</pubDate>
      <description>N4 Pharma PLC will release its unaudited interim results for the six months ending June 30, 2025, on Thursday, September 25, 2025. An online analyst briefing, hosted by the Chief Executive Officer, will take place at 9:30 am on the same day to review these results. Following the briefing, an investor presentation covering the interim results will be held at 2:00 pm, open to existing and potential shareholders.

                Disclaimer*</description>
    </item>
    <item>
      <title>Investor Event and Presentation</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/investor-event-and-presentation-1</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/investor-event-and-presentation-1</guid>
      <pubDate>Thu, 11 Sep 2025 06:00:00 GMT</pubDate>
      <description>N4 Pharma PLC will present at the ShareSoc Growth Company Seminar on Wednesday, October 8, 2025, at the Leonardo Hotel in Leeds. The event commences with registration opening at 4:30 pm and presentations starting at 5:00 pm. Nigel Theobald, Chief Executive Officer, will discuss the ongoing development of Nuvec® as a delivery system for RNA therapeutics. A link to N4 Pharma&apos;s presentation will be available on the company website after the event; however, no new material information will be disclo</description>
    </item>
    <item>
      <title>Article on Nuvec®’s Potential in RNA Therapeutics</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/article-on-nuvecrs-potential-in-rna-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/article-on-nuvecrs-potential-in-rna-therapeutics</guid>
      <pubDate>Wed, 30 Jul 2025 12:55:00 GMT</pubDate>
      <description>Article on Nuvec®’s Potential in RNA Therapeutics.</description>
    </item>
    <item>
      <title>Investor Webinar</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/investor-webinar-54</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/investor-webinar-54</guid>
      <pubDate>Mon, 14 Jul 2025 06:00:00 GMT</pubDate>
      <description>Investor Webinar.</description>
    </item>
    <item>
      <title>Directorate Change</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/directorate-change-1063</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/directorate-change-1063</guid>
      <pubDate>Tue, 08 Jul 2025 06:00:00 GMT</pubDate>
      <description>Directorate Change.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/result-of-agm-1261</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/result-of-agm-1261</guid>
      <pubDate>Mon, 30 Jun 2025 13:15:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Insight Event for Retail Investors</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/insight-event-for-retail-investors</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/insight-event-for-retail-investors</guid>
      <pubDate>Wed, 25 Jun 2025 06:00:00 GMT</pubDate>
      <description>Insight Event for Retail Investors.</description>
    </item>
    <item>
      <title>Final Results, Annual Report and Notice of AGM</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/final-results-annual-report-and-notice-of-agm-8</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/final-results-annual-report-and-notice-of-agm-8</guid>
      <pubDate>Fri, 06 Jun 2025 06:00:00 GMT</pubDate>
      <description>Final Results, Annual Report and Notice of AGM.</description>
    </item>
    <item>
      <title>Establishment of New Senior Leadership Team</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/establishment-of-new-senior-leadership-team</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/establishment-of-new-senior-leadership-team</guid>
      <pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
      <description>Establishment of New Senior Leadership Team.</description>
    </item>
    <item>
      <title>TR-1: Notification of major holdings</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/tr-1-notification-of-major-holdings-263</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/tr-1-notification-of-major-holdings-263</guid>
      <pubDate>Fri, 23 May 2025 11:37:00 GMT</pubDate>
      <description>TR-1: Notification of major holdings.</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/thalia-therapeutics-plc/news/holdings-in-company-1349</link>
      <guid isPermaLink="true">https://6ix.com/company/thalia-therapeutics-plc/news/holdings-in-company-1349</guid>
      <pubDate>Wed, 21 May 2025 15:11:00 GMT</pubDate>
      <description>Holding(s) in Company.</description>
    </item>
  </channel>
</rss>